Simulations Plus Retains Hayden IR to Develop a Comprehensive Investor Relations Program

Division: Simulations Plus

Simulations Plus, Inc. (NASDAQ: SLP), a leading provider of software for pharmaceutical discovery and development, today announced that it has retained Hayden IR, a national, New York-based investor relations consulting firm, to develop an investor relations program to raise the company’s visibility and strengthen its relationships with the investment community.

Walt Woltosz, chairman and chief executive officer of Simulations Plus, commented: “Simulations Plus has demonstrated the consistent ability to generate earnings and cash, while strengthening its balance sheet and improving its strategic position. We continue to expand our product line and services and add to our Life Sciences team, setting the stage for accelerating top-line growth. Our Board of Directors is committed to translating this performance into enhanced shareholder value, and we believe the time is right to engage Hayden IR to broaden our exposure with investors. Hayden IR comes highly recommended as an agency that can introduce us to new institutional shareholders who will understand our strategy and embrace our business model.”

With offices in New York, Phoenix, Minneapolis and San Diego, Hayden IR provides a comprehensive range of investor relations services to a growing list of clients. For more than a decade, Hayden IR has been a recognized leader in driving market recognition and creating sustainable competitive advantages for more than 100 micro- and small-cap companies. Hayden delivers expertise and professionalism in such areas as investor management, relationship building, awareness campaigns, online presence and corporate identity.

Jeffrey Stanlis, Partner at Hayden IR, added: “Simulations Plus represents an exciting opportunity for investors to benefit from, and participate in, technology advances in the life sciences and pharmaceutical development. We believe this is a compelling investment for a wide range of small-cap and mid-cap investors. Simulations Plus has demonstrated an ability to grow revenue—while maintaining 70+% gross margin and solid double-digit operating margin—even in a challenging economy. Its best-in-class pharmaceutical software offerings continue to create opportunities for continuing growth with leading pharmaceutical organizations. In fiscal 2009, the company generated more than $1.5 million in cash even after increasing research and development spending, marketing and sales activities, and funding more than $1 million for share repurchases. The Company built on this success with record revenue and profitability in the first quarter of fiscal 2010. We believe Simulations Plus is well-positioned for the future and represents an exciting, high-margin investment in an industry segment with compelling long-term trends.”